Inozyme Pharma

$8.31 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Inozyme Pharma

Inozyme Pharma, Inc. is a rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

Stock Analysis

last close $8
1-mo return -14.4%
3-mo return -48.9%
avg daily vol. 29.04T
52-week high 29.46
52-week low 7.66
market cap. $189M
forward pe -
annual div. -
roe -33.3%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 86.3%
baraka

Subscribe now for daily local and international financial news

Subscribe